Last reviewed 2026-04-22 · How we verify

IDP-118 Lotion

IDP-118 Lotion is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.

IDP-118 Lotion is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin. Used for Atopic dermatitis, Plaque psoriasis, Other inflammatory dermatoses.

At a glance

Mechanism of action

IDP-118 contains a potent corticosteroid formulated as a lotion for topical application. It works by binding to glucocorticoid receptors in skin cells, reducing inflammatory cytokine production and suppressing local immune cell activity. This mechanism makes it effective for inflammatory skin conditions characterized by erythema, pruritus, and scaling.

Approved indications

• Atopic dermatitis
• Plaque psoriasis
• Other inflammatory dermatoses

Common side effects

• Application site irritation
• Skin atrophy
• Folliculitis

Key clinical trials

• Duobrii Treatment of Acne Keloidalis Nuchae (AKN) (PHASE3)
• A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis (PHASE4)
• Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
• A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis (PHASE4)
• Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
• Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis (PHASE4)
• A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. (EARLY_PHASE1)
• Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.